Clinical trials: Adult Myelodysplastic Syndrome
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells and prepares the…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00376519
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced MDS Without Identical Sibling Donor
Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%).
- Trial name
- NCT01793675
- Testing
- transplant with haploidentical donor
- Where
- 8 sites in China
- Volunteers
- 116 people
- Sponsor
- Peking University People's Hospital
Thrombocytopenia, MDS
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)
The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.
- Conditions
- Thrombocytopenia, MDS, Myelodysplastic Syndromes, Refractory Cytopenias
- Trial name
- NCT00303472
- Testing
- Romiplostim
- Volunteers
- 72 people
- Sponsor
- Amgen
Cancer, Leukemia
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
In this study two cord blood collections will be used to increase the number of cord blood cells you will receive on transplant day. We call this a "double unit" cord blood transplant.
- Conditions
- Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT00597519
- Testing
- Fludarabine, Cyclophosphamide, Transplantation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- Trial name
- NCT04517175
- Testing
- Flow cytometry
- Volunteers
- 300 people
- Sponsor
- Maastricht University
Myelodysplastic Neoplasm, Myelodysplastic Syndrome
Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms
Hypocellular myelodysplastic neoplasms (h-MDS) are a distinct entity introduced in the 2022 WHO classification. They are characterized by reduced bone marrow cellularity and may share several clinical, morphological…
- Trial name
- NCT07825207
- Testing
- Eltrombopag (ELT)
- Where
- 26 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic Syndromes
Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome
The main objective of this trial is to evaluate the efficacy and toxicity of intensive immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion dependent low and intermediate risk myelodysplastic…
- Trial name
- NCT00004208
- Testing
- ATG + CSA, Supportive care
- Where
- Switzerland
- Volunteers
- 86 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Leukemia
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006225
- Testing
- filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin
- Where
- United States
- Sponsor
- Northwestern University
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- ALLO-WT1 (NCT01819558)
- Testing
- recwt1-A10+AS01B
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Paoli-Calmettes
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00589563
- Testing
- anti-thymocyte globulin, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Cancer
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
RATIONALE: Donor mesenchymal stem cell infusion may be an effective treatment for acute or chronic graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00361049
- Testing
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS.
- Trial name
- NCT00656617
- Testing
- Idarubicin, Cytarabine, Vorinostat
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
This was a single-center, single-dose, open-label clinical study. 12 subjects were randomly assigned in a 1:1 ratio to one of the following dosing sequences (sequence 1: AB; Sequence 2: BA).
- Trial name
- NCT05828485
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Multiple Myeloma, Acute Myeloid Leukemia
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
- Trial name
- NICHE (NCT04645199)
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Myelodysplastic Syndromes
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.
- Trial name
- NCT03184935
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Decitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
- Trial name
- NCT04022785
- Testing
- Azacitidine, BRD4 Inhibitor PLX51107
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.